Cagrilintide

Cagrilintide is a long-acting analog of the hormone amylin, which is co-secreted with insulin by pancreatic beta cells. It has been studied for its effects on appetite regulation, weight loss, and metabolic health. Cagrilintide works by activating the amylin receptor complex, which influences satiety signals in the brain and slows gastric emptying. It remains experimental outside of clinical trials and is not FDA-approved as a therapy at this time.

How It Is Used in Research Settings

• Studied for reducing food intake and body weight in models of obesity.
• Explored in combination with GLP-1 receptor agonists (such as semaglutide) for enhanced weight loss and metabolic improvements.
• Investigated for improving insulin sensitivity and glycemic control in type 2 diabetes research.
• Examined in long-term metabolic studies for cardiovascular and metabolic risk reduction.

Proposed Uses (Research Areas)

• Obesity and weight management research.
• Type 2 diabetes and metabolic syndrome studies.
• Combination therapy research with GLP-1 receptor agonists for synergistic metabolic effects.
• Cardiovascular and endocrine health models.

How It Is Dosed in Research Settings

• Injectable: Subcutaneous administration, typically studied at 0.3–4.5 mg once weekly in clinical research.
• Combination protocols: Investigated alongside GLP-1 analogs such as semaglutide for additive weight loss and glycemic benefits.
• Cycle length: Long-term trials often extend 26–68 weeks, reflecting chronic disease management models.
• Handling: Provided in solution for injection in clinical studies; stored refrigerated and protected from light per research SOPs.

Important Considerations

• Regulatory status: Cagrilintide is not FDA-approved at this time; it remains under investigation in clinical trials.
• Evidence base: Clinical studies show promising weight loss results, especially in combination with GLP-1 therapies, but further trials are ongoing.
• Safety: Reported side effects in research include nausea, vomiting, gastrointestinal discomfort, and decreased appetite. Long-term safety data is still being gathered.

Disclaimer

This material is provided for educational purposes only and summarizes published research on Cagrilintide.
It is not medical advice. Cagrilintide is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.

This peptide is for research use only.